Answer the questions below and we'll guide you
The participants in the studies were 43,522 with DPP-4 inhibitors, 60,080 with GLP-1RA, and 77,541 with SGLT-2 inhibitors, for a total number of 181,143 participants
On December 18, 2025, Novo Nordisk applied for FDA approval of a two-drug combination called CagriSema
Du Y-L, Liang Y, Cao Y, Liu L, Li J, Shi G-Q
Consultation and Coaching Program If you decide to move forward with the consultation, we will discuss your medical history, BMI and your needs so that we can assist you in making two decisions: whether to get compounded semaglutide/tirzepatide or a prescription and whether you should do the 6-month Program that includes patient-led scheduling for coaching, labs, scale and journal vs the Non-coaching enrollment program that does NOT include a 6-month coaching program but does include labs, scale, and journal